ABSTRACT
It is a reality that most of the development of new drugs is undertaken by the pharmaceutical industry. This chapter explores the ethical questions, dilemmas and pitfalls that the author encountered whilst working in the development of medicinal cannabis. The author wanted to explore the problems of working alongside the pharmaceutical industry in developing a major ‘new’ pharmaceutical, whilst at the same remaining independent and ‘distanced’ from commercial issues. He reflects on his own experiences with the pharmaceutical industry although the principles remain the same for other medical technologies. The use of the Freedom of Information Act may reveal the extent of any doctor’s involvement with industry. The need to be able to demonstrate that fees are justifiable and ethical may become increasing frequent. The author explains the concept of bundling, and mentions that he attempted to maintain his independence although it has been difficult at times to identify the ethical boundaries.
